Plain-English translation of NCT07557849 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →This study is building a comprehensive database of pancreatic cancer patients who have a KRAS gene mutation and are receiving targeted therapy designed to fight this specific mutation. Researchers are collecting medical information from both past and current patients at major cancer centers to understand how well these newer treatments work and which patients benefit most from them.
Pancreatic cancer is very serious and standard chemotherapy doesn't work well for many patients. Now that doctors have developed new medications that target the specific genetic mutations in pancreatic cancer cells, this study exists to track how effective these treatments are and learn which patients respond best to them, so doctors can make better treatment decisions in the future.
You likely qualify if…
You likely don't qualify if…
If you join this study, researchers will collect information from your medical records about your diagnosis, the type of KRAS mutation you have, your treatment history, and how you responded to the medication. Some participants are being studied from their past medical records, while others will have their information collected going forward as they continue their cancer treatment. The study team will regularly update and maintain this information over time.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China
Sponsor
Fudan University
Enrollment target
~1,000 participants
Started
May 2026
Primary completion
April 2028
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yi Liu, MD
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.